Summary
HAE Chart
Understanding Haemonetics (HAE) Reliance on International Revenue
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q1 2026 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christopher A. Simon - CEO, President & Director James C.
Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Haemonetics Corporation Dividends
Haemonetics Corporation Earnings
| 6 Nov 2025 (In 2 months) Date | | 1.11 Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | 1.16 Cons. EPS | - EPS |
| 7 Aug 2025 Date | | 1.02 Cons. EPS | 1.1 EPS |
| 7 Aug 2025 Date | | 1.02 Cons. EPS | 1.1 EPS |
| 6 Aug 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2025 (In 2 months) Date | | 1.11 Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | 1.16 Cons. EPS | - EPS |
| 7 Aug 2025 Date | | 1.02 Cons. EPS | 1.1 EPS |
| 7 Aug 2025 Date | | 1.02 Cons. EPS | 1.1 EPS |
| 6 Aug 2025 Date | | - Cons. EPS | - EPS |
Haemonetics Corporation (HAE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Haemonetics Corporation ever had a stock split?
Haemonetics Corporation Profile
| Medical - Instruments & Supplies Industry | Healthcare Sector | Christopher A. Simon CEO | NYSE Exchange | 405024100 Cusip |
| US Country | 3,657 Employees | - Last Dividend | 3 Dec 2012 Last Split | 9 May 1991 IPO Date |
Overview
Haemonetics Corporation is a leading healthcare provider that specializes in developing a comprehensive suite of medical products and solutions. With a global presence, the company is dedicated to enhancing the efficiency and safety of blood and plasma collection, processing, and management. Founded in 1971 and headquartered in Boston, Massachusetts, Haemonetics Corporation has been at the forefront of innovation, offering advanced technologies to support hospitals, blood banks, and plasma collection centers in improving patient care and outcomes.
Products and Services
- Automated Plasma Collection Systems and Software Solutions:
Includes NexSys PCS and PCS2 plasmapheresis equipment, related disposables, and intravenous solutions. Offers integrated IT platforms like NexLynk DMS donor management system and Donor360, designed for plasma customers to streamline donor management, operations, and supply chain management.
- Automated Blood Component and Manual Whole Blood Collection Systems:
Features the MCS brand apheresis equipment, which enables the collection of specific blood components from donors. Also provides disposable collection and component storage sets, SafeTrace Tx blood bank information system, and BloodTrack management software, facilitating efficient blood management and transfusion processes.
- Hospital Products:
Offers TEG, ClotPro, and HAS hemostasis analyzer systems for a comprehensive assessment of a patient's hemostasis. TEG Manager software connects TEG analyzers across the hospital, allowing clinicians remote access to test results to inform treatment decisions. Cell Saver Elite +, an autologous blood recovery system, is suited for various surgeries, enhancing recovery and minimizing transfusion needs.
- VASCADE Products:
Including VASCADE and VASCADE MVP, this technology platform leverages the natural clotting mechanism with a catheter-based delivery system for vascular closure, designed to improve patient outcomes and reduce recovery time after procedures.
Contact Information
